These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 11930299

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.
    Ebert EC, Das KM, Mehta V, Rezac C.
    Clin Exp Immunol; 2008 Dec; 154(3):325-31. PubMed ID: 18826498
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J, López-Larrea C, González S, Fuentes D, Dieguez A, Deschamps EM, Pérez-Pariente JM, López-Vázquez A, de Francisco R, Rodrigo L.
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?
    Rutgeerts P, Vermeire S, Van Assche G.
    Gut; 2007 Apr; 56(4):453-5. PubMed ID: 17369375
    [Abstract] [Full Text] [Related]

  • 10. New cytokine therapeutics for inflammatory bowel disease.
    Stokkers PC, Hommes DW.
    Cytokine; 2007 Apr; 28(4-5):167-73. PubMed ID: 15588691
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term safety of Infliximab for the treatment of inflammatory bowel disease: does blocking TNFalpha reduce colitis-associated colorectal carcinogenesis?
    Biancone L, Petruzziello C, Calabrese E, Zorzi F, Naccarato P, Onali S, Pallone F.
    Gut; 2009 Dec; 58(12):1703. PubMed ID: 19923350
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF.
    Holtmann MH, Galle PR, Neurath MF.
    Am J Gastroenterol; 2003 Feb; 98(2):504-5. PubMed ID: 12591081
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
    Pierik M, Vermeire S, Steen KV, Joossens S, Claessens G, Vlietinck R, Rutgeerts P.
    Aliment Pharmacol Ther; 2004 Aug 01; 20(3):303-10. PubMed ID: 15274667
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. New therapies for inflammatory bowel disease: an update on chimeric anti-TNF alpha antibodies and IL-10 therapy.
    van Hogezand RA, Verspaget HW.
    Scand J Gastroenterol Suppl; 1997 Aug 01; 223():105-7. PubMed ID: 9200315
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.